Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
- Written by PR Newswire
HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the National Center for Drug Evaluation of the State Drug Administration of the People's...
Read more: Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA














